S&P Futures
5,889.00 -3.50 (-0.06%) Dow Futures
43,050.00 -119.00 (-0.28%) Nasdaq Futures
20,522.50 -19.50 (-0.09%) Russell 2000 Futures
2,244.90 -1.30 (-0.06%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,753.40 -6.40 (-0.23%)
Silexion Therapeutics Corp (SLXN)
After hours:
| Previous Close | 0.3359 |
| Open | 0.3424 |
| Bid | 0.3003 x 100 |
| Ask | 0.3049 x 100 |
| Day's Range | 0.3326 - 0.4600 |
| 52 Week Range | 0.2720 - 13.5580 |
| Volume | |
| Avg. Volume | 2,454,065 |
| Market Cap | 6.221M |
| Beta (5Y Monthly) | -0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6600 |
| Earnings Date | Nov 12, 2024 - Nov 18, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
GRAND CAYMAN, CAYMAN ISLANDS / ACCESSWIRE / October 9, 2024 / Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its ...
Business WireSilexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
GRAND CAYMAN, Cayman Island, October 01, 2024--Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit the growth and induce necrosis
